Key Market Indicator:
F&G: 14
25.838,90 NASDAQ · 47.579,00 DOW · 6.876,60 S&P · 3.937,61 Gold · 64,70 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© Globe Newswire
06.11.2025
ISIN: US70805E1091
Pennant Group Inc
PNTG
LISTED
NASDAQ
Pennant Group to Participate in the 2025 Stephens Annual Investment Conference
Article
News Preview
Pennant Group to participate in 2025 Stephens Investment Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
Article
News Preview
REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US1710774076
Niagen Bioscience Inc
CDXC
LISTED
NASDAQ
Niagen Bioscience Announces $10 Million Share Repurchase Program
Article
News Preview
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximate...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
06.11.2025
ISIN: US8816242098
Teva Pharmaceutical Industries Limited
TEVA
LISTED
NYSE
Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments
Article
News Preview
MONTRÉAL, Nov. 6, 2025 /CNW/ - Teva Canada welcomes the recent announcement from Québec's Ministry of Health regarding changes to the reimbursement framework for extended-release methylphenidate products. Effective December 11, 2025, the Régie de l'assurance maladie du Québec (RAMQ) will apply the "lowest price"...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
06.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response
Article
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
Article
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting
Article
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for sa...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Wellcare of Georgia Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
Article
News Preview
Medicare Advantage plans will be available to more than 51 million beneficiaries in 32 states; Prescription Drug Plans will continue to be offered nationwide. New in 2026 Wellcare to transition Medicare-Medicaid Plans (MMPs) demonstration...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US28036F1057
Edgewise Therapeutics Inc
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Article
News Preview
–  Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – –  MESA open-label extension trial of sevasemten in...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US6700021040
Novavax Inc
NVAX
LISTED
NASDAQ
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Article
News Preview
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfers...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US2289031005
Artivion Inc
AORT
LISTED
NYSE
Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial
Article
News Preview
ATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcev...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
Article
News Preview
REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, a...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
06.11.2025
ISIN: US51654W1018
Lantern Pharma Inc.
LTRN
LISTED
NASDAQ
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
Article
News Preview
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2025 operating and financial results webcast on Thu...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting
Article
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting. “GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-rea...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US81728J1097
Sensus Healthcare, Inc.
SRTS
LISTED
NASDAQ
Sensus Healthcare Named to TIME’s America’s Growth Leaders of 2026
Article
News Preview
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME’s list of America’s Growth Leaders of 2026, developed in partnership with Statista Inc....
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Article
News Preview
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of pl...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Article
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA™ (donidalorsen), the first and only RNA-targeted prophylactic medicine for hereditary angioedema (HAE), to be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida. Results demonstrat...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US14167L1035
CareDx Inc
CDNA
LISTED
NASDAQ
CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025
Article
News Preview
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data presentations featuring CareDx technologies at American Society of...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US75120L1008
Rallybio Corp
RLYB
LISTED
NASDAQ
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Article
News Preview
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. “In the third quarter, we con...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US2546041011
Disc Medicine Inc
IRON
LISTED
NASDAQ
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: CA82621K1021
Sienna Senior Living Inc
SIA
LISTED
TSX
Sienna Expands Retirement Portfolio in Key Ontario Market
Article
News Preview
MARKHAM, Ontario, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) announced today that it has entered into a purchase agreement to acquire The Hygate on Lexington (“Hygate”), a 216-suite retirement residence in Waterloo, Ontario....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US45175G2075
ImageneBio, Inc
IMA
LISTED
NASDAQ
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
Article
News Preview
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced managem...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Article
News Preview
Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon’s Executive Board Chair; Joe Morri...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US64135M1053
Neurogene Inc
NGNE
LISTED
NASDAQ
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Article
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. N...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US64049M2098
Neogenomics Inc
NEO
LISTED
NASDAQ
NeoGenomics to Participate in Upcoming Investor Conferences
Article
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: Stephens Annual Investment Conference in Nashville, TN Company presentation on Wednesday, November 19, at 1:00 pm CT, accessible here Piper Sandl...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US8006771062
Sangamo Therapeutics Inc
SGMO
LISTED
NASDAQ
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Article
News Preview
SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2025 FINANCIAL RESULTS...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: CA94947L1022
WELL Health Technologies Corp
WELL
LISTED
TSX
WELL Health Reports Record Revenue, Record Adjusted EBITDA, and Record Adjusted Net Income in Q3-2025 Driven by Strong Performance in Core Canadian Businesses
Article
News Preview
WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) (the “Company” or “WELL”), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce its interim consolidated financial results for the quarter ended September...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: IL0011407140
Urogen Pharma Ltd
URGN
LISTED
NASDAQ
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
Article
News Preview
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Article
News Preview
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US55287L1017
MBX Biosciences, Inc.
MBX
LISTED
NASDAQ
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Article
News Preview
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP)...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US24906P1093
DENTSPLY SIRONA Inc
XRAY
LISTED
NASDAQ
Dentsply Sirona Reports Third Quarter 2025 Results
Article
News Preview
CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2025 and introduced its Return-to-Growth action plan, a comprehensive strategy to improve performance and position the Company for sustained, profitable growth o...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US98887Q1040
Zai Lab Limited
ZLAB
LISTED
NASDAQ
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Article
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering the next phase of our growth, powered by the rapid advancement of our global pipeline and supported by a commercially profitable and scalable business in China...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: CA24874B1085
dentalcorp Holdings Ltd.
DNTL
LISTED
TSX
Dentalcorp Reports Third Quarter 2025 Results
Article
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL), Canada’s largest and one of North America’s fastest growing networks of dental practices, today announced its financial and operating results for the third quarter ended September 30, 2025. All financial figures are in Canadian dollars unless otherwise indicated. “We delivered...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US03237H1014
Amylyx Pharmaceuticals Inc
AMLX
LISTED
NASDAQ
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
Article
News Preview
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025. “Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial,”...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US98422E1038
Xeris Biopharma Holdings Inc
XERS
LISTED
NASDAQ
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
Article
News Preview
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by i...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US01438T1060
Aldeyra Therapeutics Inc
ALDX
LISTED
NASDAQ
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Article
News Preview
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that the company will host a Research & Development Update webcast on Thursday, November 13, 2025 at 8:00 a.m. ET. Aldeyra will provide a review of pipeline...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: GB0009895292
AstraZeneca PLC
AZN
LISTED
LSE
AstraZeneca's 9M and Q3 2025 Financial Results
Article
News Preview
AstraZeneca: Revenue and EPS summary   9M 2025 % Change Q3 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 41,035 9   9   14,365 11   9   - Alliance Revenue 2,108 41   41   815 46   44   Product Revenue2 43,143 10...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US92556V1061
Viatris Inc
VTRS
LISTED
NASDAQ
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Article
News Preview
Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
Article
News Preview
Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluatin...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Article
News Preview
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organic Q4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectively FY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organic FY25 GAAP EPS o...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: CA22717L1013
Cronos Group. Inc.
CRON
LISTED
TSX
Cronos Group Reports 2025 Third Quarter Results
Article
News Preview
Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: KYG2545C1042
Crescent Biopharma, Inc.
CBIO
LISTED
NASDAQ
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Article
News Preview
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US00887A2042
Rein Therapeutics Inc
ALRN
LISTED
NASDAQ
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Article
News Preview
New data builds on prior results, highlights LTI-03's differentiated approach, and supports the ongoing global Phase 2 RENEW trial New data builds on prior results, highlights LTI-03's differentiated approach, and supports the ongoing global Phase 2 RENEW trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Therapeutics Reports Third Quarter 2025 Results
Article
News Preview
Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Article
News Preview
Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference
Article
News Preview
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-appro...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US19459J1043
Collegium Pharmaceutical Inc
COLL
LISTED
NASDAQ
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Article
News Preview
– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year –...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US09203E1055
Black Diamond Therapeutics Inc
BDTX
LISTED
NASDAQ
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Article
News Preview
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update....
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US45784P1012
Insulet Corp
PODD
LISTED
NASDAQ
Insulet Reports Third Quarter 2025 Results
Article
News Preview
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Board Increases Dividend for 54th Consecutive Year
Article
News Preview
FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
Article
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following letter to the Board of Directors of STAAR after reviewing STAAR’s third quarter earnings press release an...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure to Announce Third Quarter 2025 Financial Results
Article
News Preview
~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Monday, November 10, 2025 at 8:30 a.m. ET ~...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: CA01559R1038
Algernon Pharmaceuticals Inc.
AGN
LISTED
CSE
Algernon Health Announces Private Placement
Article
News Preview
VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross proceeds of $500,000 (the “Offering”) of units (the “Units”) at an issue price of $0.07 per...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US28658R1068
Climb Bio, Inc
CLYM
LISTED
NASDAQ
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Article
News Preview
PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated ...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US00534A1025
Invivyd Inc
IVVD
LISTED
NASDAQ
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Article
News Preview
NEW HAVEN, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights....
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
ISIN: US4050241003
Haemonetics Corp
HAE
LISTED
NYSE
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Article
News Preview
Financial release and supplemental presentation accessible online BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which end...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US03837C1062
Apyx Medical Corp
APYX
LISTED
NASDAQ
Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
Article
News Preview
CLEARWATER, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US75383L1026
Rapport Therapeutics Inc.
RAPP
LISTED
NASDAQ
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Article
News Preview
BOSTON and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the th...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
ISIN: US53220K5048
Ligand Pharmaceuticals Inc
LGND
LISTED
NASDAQ
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Article
News Preview
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 09.11.2025, Calendar Week 45, 313th day of the year, 52 days remaining until EoY.